These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 28918016)

  • 1. Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.
    Chakraborty C; Sharma AR; Sharma G; Doss CGP; Lee SS
    Mol Ther Nucleic Acids; 2017 Sep; 8():132-143. PubMed ID: 28918016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic advances of miRNAs: A preclinical and clinical update.
    Chakraborty C; Sharma AR; Sharma G; Lee SS
    J Adv Res; 2021 Feb; 28():127-138. PubMed ID: 33364050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 4. Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.
    Qiu Y; Lam JK; Leung SW; Liang W
    Molecules; 2016 Sep; 21(9):. PubMed ID: 27657028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug.
    de Brito E Cunha D; Frederico ABT; Azamor T; Melgaço JG; da Costa Neves PC; Bom APDA; Tilli TM; Missailidis S
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases.
    Bansal P; Arora M
    Adv Exp Med Biol; 2020; 1229():369-381. PubMed ID: 32285425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.
    Park J; Park J; Pei Y; Xu J; Yeo Y
    Adv Drug Deliv Rev; 2016 Sep; 104():93-109. PubMed ID: 26686832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery vehicles for small interfering RNA in vivo.
    de Fougerolles AR
    Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development.
    Humphreys SC; Thayer MB; Campbell J; Chen WLK; Adams D; Lade JM; Rock BM
    J Med Chem; 2020 Jun; 63(12):6407-6422. PubMed ID: 32352779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA and diseases: therapeutic potential as new generation of drugs.
    Wahid F; Khan T; Kim YY
    Biochimie; 2014 Sep; 104():12-26. PubMed ID: 24859535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Risks of miRNA Therapeutics: In a Drug Target Perspective.
    Zhang S; Cheng Z; Wang Y; Han T
    Drug Des Devel Ther; 2021; 15():721-733. PubMed ID: 33654378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.
    Xie Y; Wang Y; Li J; Hang Y; Oupický D
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Mar; 11(2):e1528. PubMed ID: 29700990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the Effect of miRNA on siRNA-PEI Polyplexes.
    Meneksedag-Erol D; Tang T; Uludağ H
    J Phys Chem B; 2015 Apr; 119(17):5475-86. PubMed ID: 25844922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals.
    Sarmento B
    Ther Deliv; 2010 Aug; 1(2):231-5. PubMed ID: 22816130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status and development of miRNA and siRNA research on gastric cancer].
    He M; Wang ZW
    Yi Chuan; 2011 Sep; 33(9):925-30. PubMed ID: 21951792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.